12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Company News  |  Deals

Simcere, Bristol-Myers deal

Bristol-Myers and Simcere expanded a 2010 deal to include the development and commercialization of subcutaneous Orencia abatacept in China to treat rheumatoid arthritis (RA). Simcere will be responsible for conducting and funding development and regulatory activities required for approval in China, and the two parties will share...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >